Case # ROP right eye ROP left eye Postmenstrual age when course started Duration of therapy (days) Therapy effect Cortisol   -1 ng/ml Cortisol- 2 ng/ml Cortisol -3 ng/ml
1 AP AP 36 12 Y 0 0 0
2 3B+
EFP		 3B+
EFP		 35 9 Y 13.17 1.89 50.87
3 AP AP 34 16 Y 26.04 3.08 56.11
4 3B+
EFP		 3B+
EFP		 34 9 Y 0 0 0
5 AP AP 34 12 Y 0 0 0
6 AP AP 33 16 Y 19.6 6.78 59.22
7 3B+
EFP		 3B+
EFP		 35 12 Y 0 0 0
8 AP AP 36 14 Y 18.55 7.65 78.98
9 3B/4A+ 3B+
EFP		 34 12 Y 0 0 0
10 3B+EFP 3B+
EFP		 35 9 Y 0 0 0
11 3B+EFP 3B+
EFP		 34 9 Y 0 0 0
12 AP AP 35 12 Y 0 0 0
13 AP AP 34 12 Y 27.88 5.47 66.68
14 AP AP 36 9 N 24.78 4.06 75.34
15 AP AP 35 12 Y 0 0 0
16 AP AP 35 9 N 0 0 0
17 AP AP 34 12 Y 28.64 5.40 69.88
18 AP AP 34 12 Y 0 0 0
Table 2: Data of the applied therapy and the advanced stage of ROP in consecutively studied prematures in whom combined therapy was applied
Case # - consecutive patients number, ROP–retinopathy of prematurity, AP–aggressive-posterior ROP, EFP–extraretinal fibrovascular proliferation; ROP3B+ EFP – ROP 3B and ridge, fibrous component in EFP and Plus Disease, therapy effect: Y–confirmed beneficial effect of treatment, N–No beneficial effect of treatment, Cortisol-1–Cortisol titer in 1-st day of course, Cortisol-2–Cortisol titer after 14 days of completed therapy, Cortisol-3–Cortisol titer after 3 months of completed therapy, (0- no measure).